Wall Street analysts expect that Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) will announce $ 481.38 million in revenue for the current quarter, Zacks Investment Research reports. Nine analysts have issued estimates for the profits of Jazz Pharmaceuticals, with the lowest sales estimate of $ 475.55 million and the highest estimate being $ 485.49 million. Jazz Pharmaceuticals achieved sales of $ 411.86 million in the same quarter last year, indicating a positive annual growth of 16.9%. The company is expected to announce the results of its quarterly results on Tuesday, November 6.
According to Zacks analysts expect that Jazz Pharmaceuticals will report an annual revenue of $ 1.92 billion for the current fiscal year, with estimates ranging from $ 1.90 billion to $ 1.93 billion. For the following year, analysts predict that the company will report sales of $ 2.16 billion per share, with estimates ranging from $ 2.07 billion to $ 2.24 billion. The sales averages of Zacks Investment Research are an average based on a survey of sell-side research analysts following Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ: JAZZ) last published its quarterly results on Tuesday 7 August. The specialized pharmaceutical company reported $ 3.49 per share for the quarter, in addition to the $ 3.23 consensus estimate of $ 0.26. The company had sales of $ 500.48 million during the quarter compared with analysts' expectations of $ 469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%.
Several equity analysts have recently weighed on the shares. BidaskClub reduced shares of Jazz Pharmaceuticals from a & # 39; hold & # 39; credit to a & # 39; sell & # 39; credit rating in a study letter on Wednesday 12 September. Leerink Swann increased their price target on shares of Jazz Pharmaceuticals from $ 200.00 to $ 210.00 and gave the share an "outperform" rating in a study letter on Friday, August 17. Wells Fargo & Co again confirmed a "buy" rating and set a price target of $ 195.00 (higher than $ 182.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 15th. HC Wainwright again confirmed a hold & # 39; credit rating and set a price target of $ 167.00 on shares of Jazz Pharmaceuticals in a study letter on Thursday, August 9th. Finally, Seaport Global Securities confirmed a "buy" rating and set a price target of $ 207.00 on shares of Jazz Pharmaceuticals in a research note on Thursday, August 9. Two investment analysts have rated the shares with a sell rating, five have a hold rating and seventeen have assigned a buy-rating to the company's shares. The company currently has a consensus score of "Buying" and a target price target of $ 190.71.
In other news, director Rick E. Winningham sold 16,639 shares of the shares in a transaction that took place on Friday, August 10th. The stock was sold at an average price of $ 176.18, for a total value of $ 2,931,459.02. After the completion of the sale, the director now owns 15,594 shares of the company's shares, valued at approximately $ 2,747,350.92. The transaction was disclosed in a legal application to the SEC, which is available through this link. CEO Bruce C. Cozadd also sold 1,600 shares of the share in a transaction that took place on Monday, July 2. The shares were sold at an average price of $ 170.81 for a total value of $ 273,296.00. After the completion of the sale, the chief executive officer now holds directly 284,115 shares of the company's shares, valued at approximately $ 48,529,683.15. The information for this sale can be found here. In the past three months, insiders sold 33,278 shares of the company's shares to the value of $ 5,774,203. 3.90% of the stock is currently in the possession of insiders.
Hedge funds and other institutional investors have recently increased or reduced their stake in the company. Summit Trail Advisors LLC raised its shareholdings in Jazz Pharmaceuticals with 8.591.5% in the first quarter. Summit Trail Advisors LLC now owns 102,125 shares in the share capital of the specialized pharmaceutical company with a value of $ 102,000 after the purchase of 100 additional shares in the last quarter. Financial Gravity Wealth Inc. acquired a new stake in Jazz Pharmaceuticals worth $ 192,000 in the first quarter. Tiverton Asset Management LLC acquired a new stake in Jazz Pharmaceuticals worth $ 198,000 in the second quarter. Moloney Securities Asset Management LLC acquired a new interest in Jazz Pharmaceuticals worth $ 204,000 in the second quarter. Finally, FDx acquired Advisors Inc. in the second quarter a new interest in Jazz Pharmaceuticals, worth $ 244,000. 92.48% of the shares are held by institutional investors.
The shares of JAZZ traded $ 0.92 during the afternoon trade on Thursday and reached $ 161.93. 575,000 shares of the company's shares were exchanged, compared with the average volume of 487,671. The shares have a market capitalization of $ 9.85 billion, a P / E ratio of 16.81, a P / E / G ratio of 0.89 and a beta of 1.04. Jazz Pharmaceuticals has a low of 52 weeks of $ 128.58 and a height of 52 weeks of $ 184.00. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and markets pharmaceutical products for various medical needs in the United States, Europe and internationally. The company has a portfolio of products and product candidates with a focus on sleep and hematology / oncology.
Read more: Price to earnings ratio (PE), for valuing shares
Receive a free copy of Zacks research report on Jazz Pharmaceuticals (JAZZ)
Visit Zacks.com for more information about research offers from Zacks Investment Research
Receive news and ratings for Jazz Pharmaceuticals Daily – Enter your email address below to receive a concise, daily summary of the latest news and ratings from analysts for Jazz Pharmaceuticals and related companies with the FREE daily email newsletter from MarketBeat.com.